CSI Market
Sign In | Register

Zyversa Therapeutics Inc (ZVSA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ZVSA Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Zyversa Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-1.79
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.06
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.02
Impairment Of Inprocess Research And Development-
Issuance Of Common Stock Pursuant To Vendor-
Shares Issued As Consideration For Extension Of Lockup Period-
Derivative Gain Loss On Derivative Net-
Increase Decrease In Vendor Deposits-
Increase Decrease Deferred Offering Costs-
Gain Loss On Fair Value Of Converible Notes0.34
Fair Value Of Equity Payable0.03
Increase Decrease In Deferred Offering Costs-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.11
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.55
Increase (Decrease) in Security Deposits0.01
Increase (Decrease) in Prepaid Expense and Other Assets-0.09
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.80
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock1.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Deferred Offering Costs Paid-
Redemption Of Series Preferred Stock-
Proceeds From Investor Deposits-
Registration And Issuance Costs Associated With Preferred Stock Issuance-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Warrant Inducement Offer Exercise Proceeds-
Payments Of Preferred Stock Issuance Costs-
Proceeds From Pre Funded Warrant Exercises-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.80
Total Cash Flow0.20
4 historic quarters locked

Sign in to unlock the full Zyversa Therapeutics Inc cash flow history.

Sign In Create Free Account

About Zyversa Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260331)
  • Filed with the SEC: May 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-022759

Figures are derived from filed reports and may be restated. Historical data is subject to revision.